COVID-19 Incidence and Mortality in Federal and State Prisons Compared with the US Population, April 5, 2020, to April 3, 2021

TY - JOUR

T1 - COVID-19 Incidence and Mortality in Federal and State Prisons Compared with the US Population, April 5, 2020, to April 3, 2021

AU - Marquez, Neal

AU - Ward, Julie A.

AU - Parish, Kalind

AU - Saloner, Brendan

AU - Dolovich, Sharon

N1 - Funding Information: Conflict of Interest Disclosures: None reported. Disclaimer: This article reflects the views of the authors and should not be construed to represent the FDA’s views or policies. Additional Contributions: Lisa Rovin, JD, and Stella Kim, PharmD, JD (FDA Public Health Analysis and Strategy Staff), and Kristin Davis, JD (FDA Office of Generic Drug Policy), reviewed versions of the manuscript and provided valuable feedback. Andrea Monge, MD, PhD (FDA Public Health Analysis and Strategy Staff), helped categorize the data into therapeutic areas for analysis. None of the contributors received compensation for their assistance. Additional Information: This work was conducted during the authors’ employment with the FDA. This project was supported in part by Dr Fowler’s appointment to the FDA’s Public Health Strategy and Analysis Staff, administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy and the FDA. ORISE serves an administrative function to manage fellows for the Public Health Strategy and Analysis Staff; the fellows are funded solely by the FDA. 1. Center for Drug Evaluation and Research. Competitive generic therapies: guidance for industry. US Food and Drug Administration. Published March 2020. Accessed August 4, 2021. https://www.fda.gov/media/136063/download 2. Lionberger R. Generic drugs in the 21st century: FDA’s actions create transparency and value for complex generic product development. US Food and Drug Administration. Published May 5, 2021. Accessed July 1, 2021. https:// www.fda.gov/drugs/news-events-human-drugs/generic-drugs-21st-century-fdas-actions-create-transparency-and-value-complex-generic-product 3. Competitive generic therapy approvals. US Food and Drug Administration. Published 2021. Accessed August 2, 2021. https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals 4. Conrad R, Liu W, Nardinelli C, Lutter R. Estimating cost savings from generic drug approvals in 2017. US Food and Drug Administration. Published 2018. Accessed August 2, 2021. https://www.fda.gov/media/113500/download 5. Conrad R, Lutter R. Generic competition and drug prices: new evidence linking greater generic competition and lower generic drug prices. US Food and Drug Administration. Published 2019. Accessed August 2, 2021. https://www. fda.gov/media/133509/download 6. Alpern JD, Shahriar AA, Xi M, et al. Characteristics and price increases among sole-source, off-patent drugs in the United States, 2008 to 2018. JAMA Netw Open. 2020;3(8):e2013595-e2013595. doi:10.1001/jamanetworkopen.2020.13595 Funding Information: Funding/Support: Mr Marquez and Dr Dolovich were funded by the Vital Projects Fund and Arnold Ventures. Mr Marquez was funded by a National Institute of Child Health and Human Development (NICHD) P2C grant (P2C HD042828). Ms Ward was funded by a NICHD T32 grant (T32-HD 094687). Dr Saloner was funded by a Greenwall Foundation Making a Difference grant. Dr Dolovich was funded by a Centers for Disease Control and Prevention contract.

PY - 2021/11/9

Y1 - 2021/11/9

UR - http://www.scopus.com/inward/record.url?scp=85116865021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116865021&partnerID=8YFLogxK

U2 - 10.1001/jama.2021.17575

DO - 10.1001/jama.2021.17575

M3 - Letter

C2 - 34613335

AN - SCOPUS:85116865021

SN - 0098-7484

VL - 326

SP - 1865

EP - 1867

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 18

ER -